Efalizumab
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Candidates for Systemic Therapy for Psoriasis
Conditions
Candidates for Systemic Therapy for Psoriasis, Psoriasis
Trial Timeline
Oct 27, 2004 → May 30, 2006
NCT ID
NCT00287118About Efalizumab
Efalizumab is a approved stage product being developed by Merck for Candidates for Systemic Therapy for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00287118. Target conditions include Candidates for Systemic Therapy for Psoriasis, Psoriasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00287118 | Approved | Completed |
| NCT00442650 | Phase 3 | Completed |
Competing Products
2 competing products in Candidates for Systemic Therapy for Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| AMO959 + Enzalutamide + Abiraterone | Novartis | Phase 1/2 | 41 |